Fisher & Paykel Shares Testing Resistance Despite Analyst Shift: The Latest
Fisher & Paykel Healthcare (ASX: FPH) rose 0.53% to A$31.98, testing resistance near A$32. Goldman removed the stock from its APAC Conviction List, described as a portfolio/tactical shift without a rating downgrade. FY26 operating revenue was ~NZ$2.3B and NPAT ~NZ$468M. JPMorgan set Overweight with NZ$37.50; Morgan Stanley Buy with NZ$40.
How this was made
The 30-second read
Why it matters
The key incremental trading angle is the timing: Goldman’s removal from its APAC Conviction List is presented as tactical, yet it may still trigger near-term selling pressure from mandates tied to conviction lists, coinciding with the technical resistance test.
Market read
Traders can frame the setup as flow/positioning pressure into a known technical level, despite constructive earnings and buy-side endorsements.
What to watch
FX exposure (NZD/USD/EUR) and already-embedded valuation for FY27–FY28 could dominate price action more than the conviction-list mechanics.
Background
FPH is described as having delivered a strong FY26 result (revenue ~NZ$2.3B, NPAT ~NZ$468M) and ongoing FY27 growth commentary, but the stock has struggled to break above A$32 since March.
Ticker impact
Fisher & Paykel Healthcare tested resistance near A$32 while Goldman removed it from the APAC Conviction List, creating a near-term sentiment headwind.
Near-term underperformance risk versus healthcare peers until price clears the A$32 resistance level.
The article links the technical cap (since March) with the timing of Goldman’s removal, while explicitly stating no fundamental downgrade; that combination suggests flow-driven, not fundamental, pressure.
Market effects
Highlights how portfolio-conviction changes can temporarily override otherwise positive fundamentals in medical device/healthcare names.
APAC investor positioning may shift tactically away from NZ-listed healthcare exposure following Goldman’s list change.
Limited direct global read-across; mainly a sentiment/flow signal for respiratory device peers and non-invasive therapy themes.
Counterpoint
Because the article says Goldman’s removal is not a downgrade, the A$32 cap may be more about valuation/FX sensitivity than conviction-driven selling; dips could be bought if fundamentals remain intact.
Key entities
- companyFisher & Paykel Healthcare
Respiratory device maker whose shares are testing resistance near A$32 while Goldman removed it from its APAC Conviction List.
- financial_institutionGoldman Sachs
Removed FPH from its APAC Conviction List in a monthly portfolio review; article frames it as tactical rather than a downgrade.
- financial_institutionJPMorgan
Initiated coverage with Overweight and a 12-month target of NZ$37.50 (as cited in the article).
- financial_institutionMorgan Stanley
Maintained Buy rating with a NZ$40 target (as cited in the article).
